Timothy M. Mayleben - May 23, 2024 Form 4 Insider Report for Landos Biopharma, Inc. (LABP)

Role
Director
Signature
/s/ Eric W. Blanchard, Attorney-in-Fact
Stock symbol
LABP
Transactions as of
May 23, 2024
Transactions value $
$0
Form type
4
Date filed
5/23/2024, 05:45 PM
Previous filing
Jan 19, 2024
Next filing
Jun 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Stock Option (right to buy) Disposed to Issuer -1.8K -100% 0 May 23, 2024 Common Stock 1.8K $3.30 Direct F1
transaction LABP Stock Option (right to buy) Disposed to Issuer -1.8K -100% 0 May 23, 2024 Common Stock 1.8K $7.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Timothy M. Mayleben is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.